Shares of Akebia Therapeutics fell sharply premarket after it abandoned plans for a clinical trial of its anemia treatment in patients not on kidney dialysis following a meeting with the Food and Drug ...
Anemia affects almost 1 in 4 people worldwide. But while billions of people live with the disease, its signs and symptoms aren’t just part of everyday life. “Anemia is one of the most common global ...
The iron deficiency anemia therapy market is propelled by the increasing cases of IDA, majorly in women, children, and the ...
The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have ...
Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal ...
The Aplastic Anemia market presents opportunities in novel therapies, with 5+ companies and 8+ drugs in various development stages. Key focus is on innovative treatment approaches, partnerships, and ...
Disc Medicine, Inc. (($IRON)) announced an update on their ongoing clinical study. Disc Medicine, Inc. is conducting a study titled RALLY-MF: A ...
Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
The development of new or worsening anemia did not decrease Jakafi’s efficacy in treating primary or secondary myelofibrosis. Patients with primary or secondary myelofibrosis who developed new or ...
Studies show patients with chronic kidney disease (CKD) and COVID-19 are at increased risk for an intensive care unit stay and early death. Anemia is an extra risk factor.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback